Trials / Terminated
TerminatedNCT01838369
A Phase II Study of BI-505 in Smoldering Multiple Myeloma
A Single-arm, Open-label, Phase 2 Clinical Trial Evaluating Disease Response Following Treatment With BI-505, a Human Anti-Intercellular Adhesion Molecule 1 Monoclonal Antibody, In Patients With Smoldering Multiple Myeloma
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 4 (actual)
- Sponsor
- BioInvent International AB · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to investigate the effect of BI-505 on tumor burden in patients diagnosed with smoldering multiple myeloma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI-505 |
Timeline
- Start date
- 2013-03-01
- Primary completion
- 2014-12-01
- Completion
- 2014-12-01
- First posted
- 2013-04-24
- Last updated
- 2023-01-11
Locations
1 site across 1 country: Sweden
Source: ClinicalTrials.gov record NCT01838369. Inclusion in this directory is not an endorsement.